Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2007-01-23
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S492000
Reexamination Certificate
active
10506729
ABSTRACT:
Heterocyclic amides of formula (1)wherein:m is 0, 1 or 2;n is 0, 1 or 2;B is phenyl or heterocyclyl;R1is selected from for example halo, nitro, cyano, hydroxy, carboxy;R2and R3are independently selected from, for example, C5-7cycloalkyl, cyano(C1-4)alkyl, C1-4alkyl (optionally substituted with 1 or 2 R8groups), —OR8and R8;R4is independently selected from for example hydrogen, halo, nitro, cyano, hydroxy, C1-4alkyl, and C1-4alkanoyl;R8is selected from for example hydroxy, heterocyclyl, aryl, —COCOOR9, —C(O)N(R9)(R10), (R9)(R10)N— and —COOR9;R9and R10are selected from for example hydrogen, hydroxy, C1-4alkyl (optionally substituted by 1 or 2 R13);R13is selected from for example, hydroxy, C1-4alkoxy, heterocyclyl and C1-4alkanoyl;R14is selected from for example, hydrogen, halo, C1-4alkyl, C5-7cycloalkyl, C1-4alkoxy, cyano, cyano(C1-4)alkyl, —COR3, (R2)(R3)NCO—, and (R2)(R3)NSO2—;or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.
REFERENCES:
patent: 3706810 (1972-12-01), Brabander et al.
patent: 4599198 (1986-07-01), Hoover
patent: 4668769 (1987-05-01), Hoover
patent: 4720503 (1988-01-01), Witzel
patent: 4751231 (1988-06-01), Halczenko
patent: 4786641 (1988-11-01), Goldmann
patent: 4794120 (1988-12-01), Manoury
patent: 5863903 (1999-01-01), Lundgren
patent: 5998463 (1999-12-01), Hulin
patent: 6277877 (2001-08-01), Hoover et al.
patent: 2004/0002495 (2004-01-01), Sher
patent: 2004/0142938 (2004-07-01), Sher et al.
patent: 2004/0220229 (2004-11-01), Bussolotti et al.
patent: 2004/0266768 (2004-12-01), Schoenafinger et al.
patent: 200740 (1983-06-01), None
patent: 4445968 (1996-06-01), None
patent: 697403 (1996-02-01), None
patent: 0846464 (1998-06-01), None
patent: 0884050 (1998-12-01), None
patent: 0978279 (2000-02-01), None
patent: 1149580 (2001-02-01), None
patent: 1177791 (2001-07-01), None
patent: 1125580 (2001-08-01), None
patent: 1134213 (2001-09-01), None
patent: 1136071 (2001-09-01), None
patent: 1 338 594 (2003-08-01), None
patent: 1 340 500 (2003-09-01), None
patent: 1088824 (2004-01-01), None
patent: 1145717 (2004-05-01), None
patent: 2081747 (1996-03-01), None
patent: 021247565 (1990-05-01), None
patent: 04179949 (1992-06-01), None
patent: 2001 089368 (2001-04-01), None
patent: 2001 206856 (2001-07-01), None
patent: 2001247565 (2001-09-01), None
patent: 2004196702 (2004-07-01), None
patent: WO-93/25574 (1993-12-01), None
patent: WO-95/24391 (1995-09-01), None
patent: WO-96/39384 (1996-12-01), None
patent: WO-96/39385 (1996-12-01), None
patent: WO-97/09040 (1997-03-01), None
patent: WO-97/31901 (1997-09-01), None
patent: WO-97/45425 (1997-12-01), None
patent: WO 9745425 (1997-12-01), None
patent: WO-98/27108 (1998-06-01), None
patent: WO-98/40353 (1998-09-01), None
patent: WO-98/50359 (1998-11-01), None
patent: WO-99/26659 (1999-06-01), None
patent: WO-99/36393 (1999-07-01), None
patent: WO-00/42213 (2000-07-01), None
patent: WO-00/47206 (2000-08-01), None
patent: WO-01/05954 (2001-01-01), None
patent: WO-01/23347 (2001-04-01), None
patent: 01/32622 (2001-05-01), None
patent: WO-01/32654 (2001-05-01), None
patent: WO-01/52825 (2001-07-01), None
patent: WO-01/68055 (2001-09-01), None
patent: WO-01/68092 (2001-09-01), None
patent: WO-01/68603 (2001-09-01), None
patent: WO-01/94300 (2001-12-01), None
patent: WO-01/96311 (2001-12-01), None
patent: WO-01/96347 (2001-12-01), None
patent: 02/20530 (2002-03-01), None
patent: WO-02/26714 (2002-04-01), None
patent: WO-02/34718 (2002-05-01), None
patent: WO 200234718 (2002-05-01), None
patent: WO-02/080644 (2002-10-01), None
patent: WO-02/096864 (2002-12-01), None
patent: WO-02/098348 (2002-12-01), None
patent: WO-03/037864 (2003-05-01), None
patent: 03/045920 (2003-06-01), None
patent: 03/072570 (2003-09-01), None
patent: 03/074484 (2003-09-01), None
patent: 03/074485 (2003-09-01), None
patent: 03/074513 (2003-09-01), None
patent: 03/074531 (2003-09-01), None
patent: 03/074532 (2003-09-01), None
patent: 03/091213 (2003-11-01), None
patent: 2004/031193 (2004-04-01), None
patent: 2004/031194 (2004-04-01), None
patent: 2004/041780 (2004-05-01), None
patent: 2004/092158 (2004-10-01), None
patent: 2004/104001 (2004-12-01), None
patent: 2004113345 (2004-12-01), None
patent: 2005/013975 (2005-02-01), None
patent: 2005/013981 (2005-02-01), None
patent: 2005/018637 (2005-03-01), None
patent: 2005/019172 (2005-03-01), None
patent: 2005/020985 (2005-03-01), None
patent: 2005/020986 (2005-03-01), None
patent: 2005/020987 (2005-03-01), None
Birch, A., et al., “Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies,” Poster, AstraZeneca UK, CVGI Research, Mereside, Alderley Park, Macclesfield, Cheshire.
Crochet, R.A., et al., “Synthesis of Substituted Thieno[2,3-b] pyrroles,” vol. 11, 143-150 (Apr. 1974).
Freeman, S., et al., “Effect of Glucose on Rat and Human Liver Glycogen Phosphorylasea Activity and Potency of a Glycogen Phosphoylase Inhibitor,” Diabetes, 52, Supp., 1470-P, A340.
Hartman, G.D., et al., “The Synthesis of 5-Alkylaminomethylthieno[2,3-b] Pyrrole-5-Sulfonamides,” Heterocycles, 29(10):1943-1949 (1989).
Hoover, D.J., et al., “Indote-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase,” J. Med. Chem., 41:2934-2938 (1998).
Hudson, S., et al., “The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats,” J. Physiol., 539:52-53 (2002).
Jakobsen, P., et al., “Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase.,” Bioorganic Med. Chem., 9:733-744 (2001).
Martin, W.H., et al., “Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo,” PNAS, 95:1776-1781 (Feb. 1998).
McCormack, J. G., et al., “Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy,” Curr. Pharmaceutical Design, 7:1451-1474 (2001).
Rath, V.L. et al., “Activation of Human Liver Glycogen Phosphorylase by Alteration of the Secondary Structure and Packing of the Catalytic Core,” Mol. Cell, 6:139-148 (Jul. 2000).
Rosauer, K.G., et al., “Novel, 3,4-Dihydroquinolin-2(1H)-one Inhibitors of Human Glycogen Phosphorylase a,” Bioorganic & Medicinal Chemistry Letters, 13:4385-4388 (2003).
Soman, G., et al. “Aromatic Compounds as Allosteric Inhibitors of Glycogen Phosphorylase beta,” Biochimica et Biophysica Acta, 358:359-362 (1974).
Soman, G., et al., “The Nature of the Binding Site for Aromatic Compounds in Glycogen Phosphorylase beta,” Biochem. J., 147:369-371 (1975).
Teague, J., “Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat,” Diabetes, 53, Supp. 1, A365, 1521-P.
Treadway, J.L., et al., “Glycogen phosphorlase inhibitors for treatment of type 2 diabetes mellitus,” Exp. Opin. Invest. Drugs, 10(3):439-454 (2001).
Turnbull, A., et al., “Pharmacological Inhibition of Glycogen Phosphorylase (GP) Lowers Plasma Glucose in Rat Models of Type 2 Diabetes,” Diabetes, 52, Supp., 1485-P, A343.
Venkatarangan, P., et al., “Prediction of Ligand-REceptor Binding Thermodynamics by Free Energy Force Field Three-Dimensional Quantitative Structure-Activity Relationship Analysis: Applications to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase,” J. Med. Chem., 42:2169-2179 (1999).
Vertigan, H., “Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents,” Diabetes, 47, Supp., 589, A214.
Font, M. et al. “Indoles and pyridazino[4,5-b] indoles as nonnucleoside analog inhibitors of HIV-1 reverse trans
Stocker Andrew
Whittamore Paul
AstraZeneca AB
Barker Michael
Saeed Kamal A.
LandOfFree
Indole-amid derivatives which possess glycogen phosphorylase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole-amid derivatives which possess glycogen phosphorylase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole-amid derivatives which possess glycogen phosphorylase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3740373